These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 14643340)

  • 1. Design and syntheses of melanocortin subtype-4 receptor agonists: evolution of the pyridazinone archetype.
    Ujjainwalla F; Warner D; Walsh TF; Wyvratt MJ; Zhou C; Yang L; Kalyani RN; MacNeil T; Van der Ploeg LH; Rosenblum CI; Tang R; Vongs A; Weinberg DH; Goulet MT
    Bioorg Med Chem Lett; 2003 Dec; 13(24):4431-5. PubMed ID: 14643340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and syntheses of melanocortin subtype-4 receptor agonists. Part 2: discovery of the dihydropyridazinone motif.
    Ujjainwalla F; Warner D; Snedden C; Grisson RD; Walsh TF; Wyvratt MJ; Kalyani RN; Macneil T; Tang R; Weinberg DH; Van der Ploeg L; Goulet MT
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4023-8. PubMed ID: 16005624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and SAR of potent and orally bioavailable tert-butylpyrrolidine archetype derived melanocortin subtype-4 receptor modulators.
    Guo L; Ye Z; Ujjainwalla F; Sings HL; Sebhat IK; Huber J; Weinberg DH; Tang R; MacNeil T; Tamvakopoulos C; Peng Q; MacIntyre E; van der Ploeg LH; Goulet MT; Wyvratt MJ; Nargund RP
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3242-7. PubMed ID: 18479920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amine-constrained pyridazinone histamine H₃ receptor antagonists.
    Sundar BG; Bailey T; Bacon E; Aimone L; Huang Z; Lyons J; Raddatz R; Hudkins R
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5543-6. PubMed ID: 21824776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of potent, selective, and orally bioavailable 3H-spiro[isobenzofuran-1,4'-piperidine] based melanocortin subtype-4 receptor agonists.
    Guo L; Ye Z; Liu J; He S; Bakshi RK; Sebhat IK; Dobbelaar PH; Hong Q; Jian T; Dellureficio JP; Tsou NN; Ball RG; Weinberg DH; MacNeil T; Tang R; Tamvakopoulos C; Peng Q; Chen HY; Chen AS; Martin WJ; MacIntyre DE; Strack AM; Fong TM; Wyvratt MJ; Nargund RP
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4895-900. PubMed ID: 20621473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of pyridazin-3-one derivatives as potent, selective histamine H₃ receptor inverse agonists with robust wake activity.
    Hudkins RL; Aimone LD; Bailey TR; Bendesky RJ; Dandu RR; Dunn D; Gruner JA; Josef KA; Lin YG; Lyons J; Marcy VR; Mathiasen JR; Sundar BG; Tao M; Zulli AL; Raddatz R; Bacon ER
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5493-7. PubMed ID: 21782432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of a privileged structure leading to potent and selective human melanocortin subtype-4 receptor ligands.
    Bakshi RK; Hong Q; Tang R; Kalyani RN; Macneil T; Weinberg DH; Van der Ploeg LH; Patchett AA; Nargund RP
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1130-3. PubMed ID: 16364639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-Piperazinecarboxamides as potent and selective melanocortin subtype-4 receptor agonists.
    Palucki BL; Park MK; Nargund RP; Tang R; MacNeil T; Weinberg DH; Vongs A; Rosenblum CI; Doss GA; Miller RR; Stearns RA; Peng Q; Tamvakopoulos C; Van der Ploeg LH; Patchett AA
    Bioorg Med Chem Lett; 2005 Apr; 15(8):1993-6. PubMed ID: 15808454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of pyridazinone-based 5-HT(2C) agonists.
    Allerton CM; Andrews MD; Blagg J; Ellis D; Evrard E; Green MP; Liu KK; McMurray G; Ralph M; Sanderson V; Ward R; Watson L
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5791-5. PubMed ID: 19716297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4,5-dihydropyridazin-3-one derivatives as histamine H₃ receptor inverse agonists.
    Hudkins RL; Aimone LD; Dandu RR; Dunn D; Gruner JA; Huang Z; Josef KA; Lyons JA; Mathiasen JR; Tao M; Zulli AL; Raddatz R
    Bioorg Med Chem Lett; 2012 Jan; 22(1):194-8. PubMed ID: 22142542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of privileged structures for selective and potent melanocortin subtype-4 receptor ligands.
    Hong Q; Bakshi RK; Dellureficio J; He S; Ye Z; Dobbelaar PH; Sebhat IK; Guo L; Liu J; Jian T; Tang R; Kalyani RN; Macneil T; Vongs A; Rosenblum CI; Weinberg DH; Peng Q; Tamvakopoulos C; Miller RR; Stearns RA; Cashen D; Martin WJ; Chen AS; Metzger JM; Chen HY; Strack AM; Fong TM; Maclntyre E; Van der Ploeg LH; Wyvratt MJ; Nargund RP
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4483-6. PubMed ID: 20598533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and bioactivity of 6-phenyl-4,5-dihydro-3(2H)-pyridazinone derivatives.
    Wang T; Dong Y; Wang LC; Chen Z
    Arzneimittelforschung; 2007; 57(10):641-6. PubMed ID: 18074757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking.
    Ragusa G; Gómez-Cañas M; Morales P; Rodríguez-Cueto C; Pazos MR; Asproni B; Cichero E; Fossa P; Pinna GA; Jagerovic N; Fernández-Ruiz J; Murineddu G
    Eur J Med Chem; 2017 Feb; 127():398-412. PubMed ID: 28088085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pyridazine series of alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxiety.
    Lewis RT; Blackaby WP; Blackburn T; Jennings AS; Pike A; Wilson RA; Hallett DJ; Cook SM; Ferris P; Marshall GR; Reynolds DS; Sheppard WF; Smith AJ; Sohal B; Stanley J; Tye SJ; Wafford KA; Atack JR
    J Med Chem; 2006 Apr; 49(8):2600-10. PubMed ID: 16610803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of some pyridazinylacetic acid derivatives as a novel class of monoamine oxidase-A inhibitors.
    Khattab SN; Bekhit AA; El-Faham A; El Massry AM; Amer A
    Chem Pharm Bull (Tokyo); 2008 Dec; 56(12):1717-21. PubMed ID: 19043245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1-Amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid as a Tic mimetic: application in the synthesis of potent human melanocortin-4 receptor selective agonists.
    Bakshi RK; Hong Q; Olson JT; Ye Z; Sebhat IK; Weinberg DH; MacNeil T; Kalyani RN; Tang R; Martin WJ; Strack A; McGowan E; Tamvakopoulos C; Miller RR; Stearns RA; Tang W; Maclntyre DE; van der Ploeg LH; Patchett AA; Nargund RP
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3430-3. PubMed ID: 15951175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.
    Tamayo N; Liao L; Goldberg M; Powers D; Tudor YY; Yu V; Wong LM; Henkle B; Middleton S; Syed R; Harvey T; Jang G; Hungate R; Dominguez C
    Bioorg Med Chem Lett; 2005 May; 15(9):2409-13. PubMed ID: 15837335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha1-adrenoceptor antagonists. 6. Structural optimization of pyridazinone-arylpiperazines. Study of the influence on affinity and selectivity of cyclic substituents at the pyridazinone ring and alkoxy groups at the arylpiperazine moiety.
    Betti L; Corelli F; Floridi M; Giannaccini G; Maccari L; Manetti F; Strappaghetti G; Botta M
    J Med Chem; 2003 Jul; 46(16):3555-8. PubMed ID: 12877594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 5-substituted-N-arylpyridazinones as inhibitors of p38 MAP kinase.
    Jerome KD; Hepperle ME; Walker JK; Xing L; Devraj RV; Benson AG; Baldus JE; Selness SR
    Bioorg Med Chem Lett; 2010 May; 20(10):3146-9. PubMed ID: 20395140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of Tic-D-Phe Psi[CH2-CH2] isostere and its use in the development of melanocortin receptor agonists.
    Tian X; Chen X; Gan L; Hayes JC; Switzer AG; Solinsky MG; Ebetino FH; Wos JA; Pinney BB; Farmer JA; Crossdoersen D; Sheldon RJ
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1721-5. PubMed ID: 16376076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.